Clinical Trials List
2021-04-01 - 2022-06-30
Phase II
Terminated4
ICD-10B33.8
Other specified viral diseases
ICD-10B34.1
Enterovirus infection, unspecified
ICD-10B34.2
Coronavirus infection, unspecified
ICD-10B34.3
Parvovirus infection, unspecified
ICD-10B34.4
Papovavirus infection, unspecified
ICD-10B34.8
Other viral infections of unspecified site
ICD-10B97.19
Other enterovirus as the cause of diseases classified elsewhere
ICD-10B97.21
SARS-associated coronavirus as the cause of diseases classified elsewhere
ICD-10B97.29
Other coronavirus as the cause of diseases classified elsewhere
ICD-10B97.5
Reovirus as the cause of diseases classified elsewhere
ICD-10B97.6
Parvovirus as the cause of diseases classified elsewhere
ICD-10B97.81
Human metapneumovirus as the cause of diseases classified elsewhere
ICD-10B97.89
Other viral agents as the cause of diseases classified elsewhere
ICD-9079.89
Other specified viral infection in conditions classified elsewhere and of unspecified site
-
Trial Applicant
Medigen Vaccine Biologics corp.
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Completed
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
400 participants
-
Global
400 participants
